MSK Department of Medicine· @MSK_DeptOfMed · X·· 2 days agoScore70
Body · original
Today at #ESMO26: Zev Wainberg will present additional subgroup analyses from the phase 3 RASolute 302 study of daraxonrasib vs. chemotherapy in previously treated metastatic pancreatic adenocarcinoma. @MSKCancerCenter's @EileenMOReilly is the senior author.
📅 October 23 | 2:22 p.m. CEST
403 views · 13 likes · 3 reposts · 0 replies
Conference abstracts
LBA82matched by Proffered paper 1: Gastrointestinal tumour, upper digestive
Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Additional subgroup analyses from the ph3 RASolute 302 study
https://esmocongress.esmo.orgSource: MSK Department of Medicine · x.com